Biomarkers in Drug Development (eBook)

A Handbook of Practice, Application, and Strategy
eBook Download: EPUB
2011 | 1. Auflage
784 Seiten
Wiley (Verlag)
978-1-118-21042-0 (ISBN)

Lese- und Medienproben

Biomarkers in Drug Development -
Systemvoraussetzungen
195,81 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
Discover how biomarkers can boost the success rate of drug development efforts As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. Biomarkers in Drug Development is divided into eight parts: Part One offers an overview of biomarkers and their role in drug development. Part Two highlights important technologies to help researchers identify new biomarkers. Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose. Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.

MICHAEL R. BLEAVINS, PhD, is cofounder of MichiganTechnology and Research Institute. He retired fromPfizer/Warner-Lambert/Parke-Davis in 2006 and has twenty-threeyears of experience in pharmaceutical research, development, andbiomarkers with more than sixty-five peer-reviewed publications. CLAUDIO CARINI, MD, PhD, FRCPath, is Chief MedicalOfficer and Vice President for Clinical Research at Fresenius.Previously, Claudio served as Global Head of Translational Medicineat MDS and Global Head of Biomarkers at Hoffmann-La Roche. Claudiohas more than twenty years of experience in the field of immunologyand biomarkers and has authored more than 200 publications ininternational and domestic peer-reviewed journals. MALLÉ JURIMA-ROMET, PhD, is Senior Director forDevelopment and Regulatory Services at MDS Pharma Services, whereshe provides strategic and scientific consulting to pharmaceuticaland biotech sponsors, and leads drug development program teams.Mallé has authored over forty peer-reviewed publications andis an adjunct professor at the University of Montreal. RAMIN RAHBARI, MS, is cofounder and Senior Consultant atInnovative Scientific Management. Previously, Ramin has heldpositions at Pfizer, Synaptic, and Parke-Davis pharmaceuticalcompanies, leading cross-functional biomarker teams.

Erscheint lt. Verlag 20.9.2011
Sprache englisch
Themenwelt Medizin / Pharmazie Gesundheitsfachberufe
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Naturwissenschaften Chemie
Technik
Schlagworte Arzneimittelentwicklung • Biomarker • Chemie • Chemistry • Drug Discovery & Development • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Toxicology • Toxikologie • Wirkstoffforschung u. -entwicklung
ISBN-10 1-118-21042-5 / 1118210425
ISBN-13 978-1-118-21042-0 / 9781118210420
Haben Sie eine Frage zum Produkt?
EPUBEPUB (Adobe DRM)

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich